Tuberculosis pp 295-302 | Cite as

Treatment of Diseases Caused by Nontuberculous Mycobacteria

  • David Y. Rosenzweig

Abstract

Modern therapy for tuberculosis is highly effective, but the same cannot be said for treatment of nontuberculous mycobacterial (NTM) disease. The commonest and most important of these pathogens, the M avium-intracellulare-scrofulaceum complex (MAC), as well as the rapidly growing mycobacteria (RGM) M for-tuitum and M chelonae, and several less common species, exhibit resistance to most chemother-apeutic drugs so that successful treatment is a real challenge. Noteworthy exceptions including M kansasii and M marinum show more favorable drug susceptibility, and in these successful treatment is expected and more predictable.

Keywords

Tuberculosis Streptomycin Cavitation Tetracycline Dermatol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    David HL: Basis for lack of drug susceptibility of atypical mycobacteria. Rev Infect Dis 1981;3: 878–884.PubMedCrossRefGoogle Scholar
  2. 2.
    Heifets L: Qualitative and quantitative drug susceptibility test in mycobacteriology. Am Rev Respir Dis 1988;137:1217–1222.PubMedGoogle Scholar
  3. 3.
    Heifets LB, Iseman MD, Lindholm-Levy PJ, Kanes W: Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Anti-microb Agents Chemother 1985;28:570–575.Google Scholar
  4. 4.
    Heifets LB, Iseman MD, Lindholm-Levy PJ: Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother 1986;30:927–932.Google Scholar
  5. 5.
    Heifets LB: MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988;32:1131–1136.PubMedGoogle Scholar
  6. 6.
    Heifets LB, Iseman MD, Lindholm-Levy PJ: Combinations of rifampin or rifabutin plus ethambutol against M. avium complex: bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988;137:711–715.PubMedGoogle Scholar
  7. 7.
    Kuze F, Kurasawa T, Bando K, et al: In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. Rev Infect Dis 1981;3: 855–987.CrossRefGoogle Scholar
  8. 8.
    Harris GD, Johanson WG Jr, Nicholson DP: Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. Am Rev Respir Dis 1975;112:31–36.Google Scholar
  9. 9.
    Pfuetze KH, Lee VV, Riemann AF, et al: Photo-chromogenic mycobacterial pulmonary disease. Am Rev Respir Dis 1965;92:470–475.PubMedGoogle Scholar
  10. 10.
    Pezzia W, Raleigh JW, Bailey MC, et al: Treatment of pulmonary disease due to Mycobacterium kansasii: Recent experience with Rifampin. Rev Infect Dis 1981;3:1035–1039.PubMedCrossRefGoogle Scholar
  11. 11.
    Davidson PT, Goble M, Lester W: The antituberculosis efficacy of Rifampin in 136 cases. Chest 1972;61:574–578.PubMedGoogle Scholar
  12. 12.
    Ahn CH, Lowell JR, Ahn SS, et al: Chemotherapy for pulmonary disease due to Mycobacterium kansasii: Efficacies of some individual drugs. Rev Infect Dis 1981;3:1028–1034.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahn CH, Lowell JR, Ahn SS, et al: Short course chemotherapy for pulmonary disease due to M kansaii. Am Rev Respir Dis 1983;128:1048–1050.PubMedGoogle Scholar
  14. 14.
    Campbell IA: A study of 9-month treatment with rifampicin and ethambutol in pulmonary infection with M. kansasii (abstract). Bull Int Union Tuberc 1986;61:43.Google Scholar
  15. 15.
    Ahn CH, Wallace RH Jr, Steele LC, Murphy DT: Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987;135:10–76.PubMedGoogle Scholar
  16. 16.
    Wallace RJ Jr, O’Brien R, Glassroth J, Raleigh J, Dutt A: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. (ATS statement). Am Rev Respir Dis 1990;142:940–953.Google Scholar
  17. 17.
    Levine B, Chaisson RE: Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:861–868.PubMedGoogle Scholar
  18. 18.
    Sherer R, Sable R, Sonnenberg M, et al: Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:710–712.PubMedGoogle Scholar
  19. 19.
    Wolinsky E: Nontuberculous mycobacteria and associated disease. Am Rev Respir Dis 1979; 119:107–159.PubMedGoogle Scholar
  20. 20.
    Rosenzweig DY: Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: Clinical features and course in 100 consecutive cases. Chest 1979;75:115–119.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenzweig DY, Schlueter DP: Spectrum of clinical disease in pulmonary infection with Mycobacterium avium-intracellulare. Rev Infect Dis 1981;3:1046–1051.PubMedCrossRefGoogle Scholar
  22. 22.
    Etzkorn ET, Aldorando S, McAllister CK, et al: Medical therapy of Mycobacterium avium-intracellulare disease. Am Rev Respir Dis 1986; 134:442–445.PubMedGoogle Scholar
  23. 23.
    Hunter AM, Campbell IA, Jenkins PA, et al: Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium intracellular complex. Thorax 1981;36:326–329.Google Scholar
  24. 24.
    Rosenzweig DY: “Atypical” mycobacterioses. Clin Chest Med 1980;1:273–284.PubMedGoogle Scholar
  25. 25.
    Prince DS, Peterson DD, Steiner RM, et al: Infection with Mycobacterium avium complex in patients without redisposing conditions. N Eng J Med 1989;321:863–868.CrossRefGoogle Scholar
  26. 26.
    Dutt AK, Stead WW: Long-term results of medical treatment in Mycobacterium intracellular infection. Am J Med 1979;67:449–453.PubMedCrossRefGoogle Scholar
  27. 27.
    Davidson PT, Khanijo V, Goble M, et al: Treatment of disease due to Mycobacterium intracellular. Rev Infect Dis 1981;3:1052–1059.PubMedCrossRefGoogle Scholar
  28. 28.
    Ahn CH, Ahn SS, Anderson RA, et al: A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986;134:438–441.PubMedGoogle Scholar
  29. 29.
    Horsburgh CR Jr, Mason UG III, Heifets LB, South wick K, Labrecque J, Iseman MD: Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987;135:418–421.PubMedGoogle Scholar
  30. 30.
    Reich JM, Johnson RE: Mycobacterium avium complex pulmonary disease: Incidence, presentations and response to therapy in a community setting. Am Rev Respir Dis 1991;143:1381–1385.PubMedGoogle Scholar
  31. 31.
    Corpe RF: Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis 1981;3:1064–1067.PubMedCrossRefGoogle Scholar
  32. 32.
    Moran JF, Alexander LG, Staub EW, et al: Long-term results of pulmonary resection for atypical mycobacterial disease. Ann Thorac Surg 1983;35:597–604.PubMedCrossRefGoogle Scholar
  33. 33.
    Iseman MD, Sbarbaro JA, guest eds: National American College of Chest Physicians Consensus Conference of Tuberculosis. Chest 1985; 87(suppl): 139–149).Google Scholar
  34. 34.
    Gribetz AR, Damsker B, Bottone EJ, et al: Solitary pulmonary nodules due to nontuberculous mycobacteria infection. Am J Med 1981;70:39–43.PubMedCrossRefGoogle Scholar
  35. 35.
    Heifets LB, Iseman MD: Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections (editorial). Am Rev Respir Dis 1991;144:1–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Kurzrock R., Zander A, Vellekoop L, et al: Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984;77:35–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Golomb HM, Hadad LJ: Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984;16:393–401.PubMedCrossRefGoogle Scholar
  38. 38.
    Horsburgh CR: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332–1338.PubMedCrossRefGoogle Scholar
  39. 39.
    Agins BD, Berman DS, Spicehandler D, el Sadr W, Simberkoff MS, Rahal JJ: Effect of combined therapy with ansamycin, clofazimine, ethambu-tol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989;159:784–787.PubMedCrossRefGoogle Scholar
  40. 40.
    Hoy J, Mijch A, Sandland M, Grayson L, Lucas R, Dwyer B: Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients J Infect Dis 1990;161:801–805.PubMedCrossRefGoogle Scholar
  41. 41.
    Chiu J, Nussbaum J, Bozzette S, et al: Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambu-tol, rifampin, and ciprofloxacin. Ann Intern Med 1990;113:358–361.PubMedGoogle Scholar
  42. 42.
    Hsu KHK: Atypical mycobacterial infections in children. Rev Infect Dis 1981;3:1075–1080.PubMedCrossRefGoogle Scholar
  43. 43.
    Schaad VB, Votteler TP, McCracken GH, et al: Management of atypical mycobacterial lymphadenitis in childhood. J Pediatr 1979;95:356–360.PubMedCrossRefGoogle Scholar
  44. 44.
    Wallace RJ Jr: The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae. Clin Chest Med 1989;10:419–429.PubMedGoogle Scholar
  45. 45.
    Hoy JF, Rolston KVI, Hopfer RL, Bodey GP: Mycobacterium fortuitum bacteremia in patients with cancer and long-term venous catheters. Am J Med 1987;83:213–217.PubMedCrossRefGoogle Scholar
  46. 46.
    Hoffman PC, Fraser DW, Robicsek F, O’Bar PR, Mauney CU: Two outbreaks of sternal wound infections due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143:533–542.PubMedCrossRefGoogle Scholar
  47. 47.
    Clegg HW, Foster MT, Sanders WE Jr, Baine WB: Infection due to organisms of the Mycobacterium fortuitum complex after augmentation mammaplasty: clinical and epidemiologic features J Infect Dis 1983;147:427–433.PubMedCrossRefGoogle Scholar
  48. 48.
    Levy C, Cartin JA, Watkins A, et al: Mycobacterium chelonei infection of heart valves. N Engl J Med 1977;297:667–668.PubMedCrossRefGoogle Scholar
  49. 49.
    Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C: Antimicrobial susceptibility testing of 5 subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985;28:807–811.PubMedGoogle Scholar
  50. 50.
    Yew WW, Kwan SY, Ma WK, et al: Combination of ofloxacin and amikacin in treatment of sternotomy wound infection. Chest 1989;95: 1051–1055.PubMedCrossRefGoogle Scholar
  51. 51.
    Yew WW, Kwan SY, Ma WK, et al: Single daily dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection. Chest 1989;96: 1150–1152.PubMedCrossRefGoogle Scholar
  52. 52.
    Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG: Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500–514.PubMedCrossRefGoogle Scholar
  53. 53.
    Dalovisio JR, Pankey GA, Wallace RJ, Jones DB: Clinical usefulness of amikacin and doxy-cycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 1981;3:1068–1074.PubMedCrossRefGoogle Scholar
  54. 54.
    Kin R: Tetracycline therapy for atypical granuloma. Arch Dermatol 1974;110:299.CrossRefGoogle Scholar
  55. 55.
    Loria PR: Minocycline hydrochloride treatment for atypical acid-fast infection. Arch Dermatol 1976;112:517–519.PubMedCrossRefGoogle Scholar
  56. 56.
    Black MM, Eykyn S: The successful treatment for atypical fish tank granuloma (Mycobacterium marinum infections). Arch Intern Med 1986; 146:902–904.CrossRefGoogle Scholar
  57. 57.
    Chow SP, Ip FK, Lau JHK, et al: Mycobacterium marinum infection of the hand and wrist. J Bone Joint Surg [Am] 1987;69-A:1161–1168.Google Scholar
  58. 58.
    Yates MD, Grange JM, Collins CH: The nature of mycobacterial disease in southeast England, 1977–1984. J Epidemiol Community Health 1986;40:295–300.PubMedCrossRefGoogle Scholar
  59. 59.
    Banks J, Jenkins PA, Smith AP: Pulmonary infection with Mycobacterium malmoense: a review of treatment and response. Tubercle 1985; 66:197–203.PubMedCrossRefGoogle Scholar
  60. 60.
    Maloney JM, Gregg CR, Stephens DS, Manian FA, Rimland D: Infections caused by Mycobacterium szulgai in humans. Rev Infect Dis 1987; 9:1120–1126.PubMedCrossRefGoogle Scholar
  61. 61.
    Banks J, Jenkins PA: Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987;42:838–842.PubMedCrossRefGoogle Scholar
  62. 62.
    Bell RC, Higuchi JH, Donovan WN, Drasnow I, Johanson WG: Mycobacterium simiae. Clinical features and follow-up of twenty-four patients. Am Rev Respir is 1983;127:35–38.Google Scholar
  63. 63.
    Parrot RG, Grosset JH: Post-surgical outcome of 57 patients with Mycobacterim xenopi pulmonary infection. Tubercle 1988;69:47–55.PubMedCrossRefGoogle Scholar
  64. 64.
    Perrone C, Gikas A, Truffot-Perrot C, et al: Clarithromycin, sulfamethoxazole, and rifabutin activity against Mycobacterium avium-complex multiplication within human macrophages. Antimicrob Agents Chemother 1990;34:1508–1511.Google Scholar
  65. 65.
    Dautzenberg B, Truffot C, Legris S, et al: Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1991;144:564–569.PubMedCrossRefGoogle Scholar
  66. 66.
    Horsburgh CR, Havlik JA, Ellis DA, et al: Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex disease with and without chemotherapy. Am Rev Respir Dis 1991; 144:557–559.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • David Y. Rosenzweig

There are no affiliations available

Personalised recommendations